AI Verdict
PBYI has stronger fundamentals based on our AI analysis.
PBYI vs PBSV Fundamental Comparison
| Metric | PBYI | PBSV |
|---|---|---|
| Revenue | $228.4M | $2.3M |
| Net Income | $31.1M | $32,860.0 |
| Net Margin | 13.6% | 1.4% |
| ROE | 23.9% | 0.3% |
| ROA | 14.4% | 0.2% |
| Current Ratio | 2.00x | 4.03x |
| Debt/Equity | 0.17x | 0.00x |
| EPS | $0.61 | $0.00 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
PBYI vs PBSV: Frequently Asked Questions
Is PBYI or PBSV a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), PBYI has stronger fundamentals. PBYI is rated BUY (72% confidence) while PBSV is rated SELL (78% confidence). This is not investment advice.
How does PBYI compare to PBSV fundamentally?
PUMA BIOTECHNOLOGY, INC. has ROE of 23.9% vs Pharma-Bio Serv, Inc.'s 0.3%. Net margins are 13.6% vs 1.4% respectively.
Which stock pays higher dividends, PBYI or PBSV?
PBYI has a dividend yield of N/A or no dividend while PBSV has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in PBYI or PBSV for long term?
For long-term investing, consider that PBYI has BUY rating with 72% confidence, while PBSV has SELL rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about PBYI vs PBSV?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For PBYI vs PBSV, the AI consensus favors PBYI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.